Concomitant Risk Factors in Reports of Torsades de Pointes Associated with Macrolide Use: Review of the United States Food and Drug Administration Adverse Event Reporting System-Reference-Cited by-同舟云学术

Concomitant Risk Factors in Reports of Torsades de Pointes Associated with Macrolide Use: Review of the United States Food and Drug Administration Adverse Event Reporting System

Published:2002-07-15 Issue:2 Volume:35 Page:197-200
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:CLIN INFECT DIS

Author:

Shaffer Douglas,Singer Sarah,Korvick Joyce,Honig Peter

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Link

http://academic.oup.com/cid/article-pdf/35/2/197/1119027/35-2-197.pdf

Reference11 articles.

1. Viskin S, Roman F, Roden DM. Drug-induced torsades de pointes. Available at http://www.harrisonsonline.com/. Accessed 12 January 2001.

2. The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology

3. Risk of torsades de pointes with non-cardiac drugs

4. Risk Assessment for Antimicrobial Agent-Induced QTc Interval Prolongation and Torsades de Pointes

5. Ruskin J. Drug-induced QT interval prolongation and torsades de pointes. 26 April 2001. Anti-Infective Drugs Advisory Committee. US Food and Drug Administration Web site. Available at http://www.fda.gov/ohrms/dockets/ac/01/slides/3746s_01_ruskin.ppt.

Cited by 125 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prevalence of Medication Associated with QTc Prolongation Used Among Critically Ill Patients;Vascular Health and Risk Management;2024-02

2. Combining pharmacokinetic and electrophysiological models for early prediction of drug-induced arrhythmogenicity;Computer Methods and Programs in Biomedicine;2023-12

3. Adverse events with quetiapine and clarithromycin coprescription: A population‐based retrospective cohort study;Health Science Reports;2023-06

4. Approaches to Assessing the Safety of Medicines during the COVID-19 Pandemic Using the Example of Azithromycin;Safety and Risk of Pharmacotherapy;2022-10-05

5. A nationwide cohort study suggests clarithromycin-based therapy for Helicobacter pylori eradication is safe in patients with stable coronary heart disease and subsequent peptic ulcer disease;BMC Gastroenterology;2022-09-12